Del-1, an Endogenous Inhibitor of TGF-β Activation, Attenuates Fibrosis

17Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Uncontrolled activation of transforming growth factor (TGF)-β results in a wide range of pathologic conditions. Therapeutic interventions to regulate TGF-β signaling during fibrosis have been developed but the effectiveness is still limited. Here, we show that developmental endothelial locus-1 (Del-1) ameliorates fibrosis in mice by inhibiting αv integrin-mediated activation of TGF-β. Del-1 bound to αvβ6 integrin, an important activator of TGF-β, and inhibited the binding of αvβ6 integrin to the latency-associated peptide (LAP), thereby suppressing αv integrin-mediated activation of TGF-β. Lack of Del-1 increased colocalization of αv integrin and LAP in the lungs, which was reversed by Del-1 supplementation. The crucial role of Del-1 in regulating TGF-β activity was recapitulated in a mouse model of fibrosis using an adenovirus expressing inactive TGF-β1. Del-1 supplementation improved the pathological characteristics of the mice and reduced mortality. Thus, we propose that Del-1 is a negative regulator of TGF-β activation and a potential anti-fibrotic factor.

Cite

CITATION STYLE

APA

Kim, D. Y., Lee, S. H., Fu, Y., Jing, F., Kim, W. Y., Hong, S. B., … Choi, E. Y. (2020). Del-1, an Endogenous Inhibitor of TGF-β Activation, Attenuates Fibrosis. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.00068

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free